Tools
Tools
Gibbons, Peter, Verissimo, Edite, Araujo, Nuna C, Barton, Victoria, Nixon, Gemma L, Amewu, Richard K, Chadwick, James, Stocks, Paul A., Biagini, Giancarlo 
ORCID: https://orcid.org/0000-0001-6356-6595, Srivastava, Abhishek, Rosenthal, Philip J, Gut, Jiri, Guedes, Rita C, Moreira, Rui, Sharma, Raman, Berry, Neil, Cristiano, M Lurdes S, Shone, Alison, Ward, Stephen ORCID: https://orcid.org/0000-0003-2331-3192 and O'Neill, Paul M
(2010)
'Endoperoxide carbonyl falcipain 2/3 inhibitor hybrids: toward combination chemotherapy of malaria through a single chemical entity.'. Journal of medicinal chemistry, Vol 53, Issue 22, pp. 8202-6.
Abstract
We extend our approach of combination chemotherapy through a single prodrug entity (O'Neill et al. Angew. Chem., Int. Ed. 2004, 43, 4193) by using a 1,2,4-trioxolane as a protease inhibitor carbonyl-masking group. These molecules are designed to target the malaria parasite through two independent mechanisms of action: iron(II) decomposition releases the carbonyl protease inhibitor and potentially cytotoxic C-radical species in tandem. Using a proposed target "heme", we also demonstrate heme alkylation/carbonyl inhibitor release and quantitatively measure endoperoxide turnover in parasitized red blood cells.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Plasmodium falciparum resistance; |
| Subjects: | QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 256 Antimalarials QV Pharmacology > QV 34 Experimental pharmacology (General) WC Communicable Diseases > Tropical and Parasitic Diseases > WC 770 Therapy |
| Digital Object Identifer (DOI): | https://doi.org/10.1021/jm1009567 |
| Related URLs: | |
| Depositing User: | Mary Creegan |
| Date Deposited: | 11 Feb 2011 16:07 |
| Last Modified: | 25 Jan 2022 09:19 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/1728 |
Statistics
Actions (login required)
 |
Edit Item |